N-methylisatoic anhydride: structure given in first source; used to prepare N-methylanthranilyl (Mantyl) peptide derivatives [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-methylisatoic anhydride : A 3,1-benzoxazin-1,4-dione having an N-methyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 25160 |
| CHEMBL ID | 1903371 |
| CHEBI ID | 59054 |
| SCHEMBL ID | 159458 |
| MeSH ID | M0208154 |
| Synonym |
|---|
| CHEBI:59054 , |
| methyl-n-carboxyanthranilic anhydride |
| brn 0383957 |
| nsc 76087 |
| ai3-61135 |
| n-methyl ia |
| einecs 233-714-8 |
| n-methylisatoic anhydride |
| 2h-3,4(1h)-dione, 1-methyl- |
| mls002693972 , |
| n-methyl-n-carboxyanthranilic anhydride |
| nsc-76087 |
| 1-methyl-2h-3,1-benzoxazine-2,4(1h)-dione |
| 10328-92-4 |
| 2h-3,1-benzoxazine-2,4(1h)-dione, 1-methyl- |
| inchi=1/c9h7no3/c1-10-7-5-3-2-4-6(7)8(11)13-9(10)12/h2-5h,1h |
| nsc76087 |
| 1-methyl-3,1-benzoxazine-2,4-dione |
| n-methylisatoic anhydride, technical, 90% |
| smr001559907 |
| F1671-0001 |
| M0743 |
| AKOS000120557 |
| 1-methyl-1h-benzo[d][1,3]oxazine-2,4-dione |
| A800708 |
| nmia |
| HMS3094A15 |
| 2-27-00-00299 (beilstein handbook reference) |
| 7swe4b4cy2 , |
| unii-7swe4b4cy2 |
| STK328095 |
| 1-methylbenzo[d]1,3-oxazine-2,4-dione |
| CHEMBL1903371 |
| BP-12493 |
| FT-0636680 |
| SCHEMBL159458 |
| n-methyl-isatoic acid anhydride |
| n-methyl isatoic anhydride |
| 1-methyl-3,1-benzoxazine-2,4(1h)-dione |
| 1-methyl-1h-3,1-benzoxazine-2,4-dione |
| n-methylisatoic acid anhydride |
| DTXSID8065036 |
| 2h-3,1-benzoxazine-2,4(1h)-dione, n-methyl-, |
| 1-methyl-2h-3,1-benzoxazine-2,4(1h)-dione # |
| 2h-3,1-benzoxazine-2,4(1h)-dione,n-methyl |
| J-523685 |
| n-methylsatoc anhydrde |
| J-000923 |
| mfcd00006815 |
| isatoic anhydride, n-methyl- |
| SY013490 |
| Q27126419 |
| CS-0008011 |
| HY-18407 |
| nmianmia |
| F12822 |
| 1-methyl-2,4-dihydro-1h-3,1-benzoxazine-2,4-dione |
| EN300-20985 |
| n-methylisatioc anhydride |
| 1-methyl-1h-benzo(d)(1,3)oxazine-2,4-dione |
| Z104485728 |
| Class | Description |
|---|---|
| benzoxazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acid sphingomyelinase | Homo sapiens (human) | Potency | 31.6228 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 40.6765 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID687264 | Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei S427 after 48 hrs by Alamar Blue assay | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Identification and development of the 1,4-benzodiazepin-2-one and quinazoline-2,4-dione scaffolds as submicromolar inhibitors of HAT. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||